外显子
肺癌
癌症研究
突变
遗传学
癌症
生物
医学
肿瘤科
基因
作者
Ming Liu,Jun Zhao,D. Abulizi,Xue Hou
出处
期刊:ESMO open
[Elsevier]
日期:2024-03-01
卷期号:9: 102612-102612
标识
DOI:10.1016/j.esmoop.2024.102612
摘要
EGFR exon 20 insertions (ex20ins)-positive non-small cell lung cancer (NSCLC) is an uncommon disease with limited therapeutic options and a dismal prognosis. Furmonertinib is a novel 3rd generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed with a unique chemical structure to improve potency and specificity targeting various EGFR mutations and has been verified its superior efficacy and favorable safety profile in previous studies. We performed this study to investigate the efficacy and safety of furmonertinib for advanced NSCLC patients harboring EGFR ex20ins mutations.
科研通智能强力驱动
Strongly Powered by AbleSci AI